BHC · XBRL financial data

Bausch Health Companies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	8,027	8,434	8,124	8,757	9,625	10,266
Selling, general and administrative	2,367	2,624	2,625	2,917	3,296	3,438
Other operating income (expense)	(454)	(373)	(35)	(28)	(247)	(142)
Operating income (loss)	676	450	454	963	1,546	1,813
Interest income	13	7	14	26	33	48
Interest expense	1,534	1,426	1,464	1,328	1,388	1,604
Other income (expense)	(454)	(373)	(35)	(28)	(247)	(142)
Income tax expense (benefit)	(375)	(87)	83	221	239	247
Net income (loss)	(560)	(948)	(225)	(592)	(46)	157
Earnings per share, basic USD per share	(1.58)	(2.64)	(0.62)	(1.62)	(0.13)	0.42
Earnings per share, diluted USD per share	(1.58)	(2.64)	(0.62)	(1.62)	(0.13)	0.42
Weighted average shares, basic millions of shares	355	359	362	365	368	371
Weighted average shares, diluted millions of shares	355	359	362	365	368	375

Fiscal years (BHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	605	582	564	947	1,181	1,309
Inventory	1,094	993	1,090	1,544	1,595	1,629
Prepaid and other current assets	855	720	776	1,092	838	852
Total current assets	5,342	5,607	4,247	5,596	5,774	6,157
Property and equipment, net	1,567	1,598	1,600	1,707	1,780	2,074
Right-of-use asset	259	247	221	185	211	215
Goodwill	13,044	12,457	11,547	11,183	11,087	11,271
Total assets	31,199	29,202	25,686	27,350	26,523	26,366
Accounts payable	337	407	521	719	656	600
Accrued liabilities	4,576	4,791	2,988	3,133	3,422	3,344
Current portion of long-term debt	0	0	432	450	2,674	225
Total current liabilities	4,913	5,198	3,941	4,302	6,752	4,180
Long-term debt	23,925	22,654	20,334	21,938	18,942	20,592
Lease liability, non-current	227	214	184	148	165	167
Total liabilities	30,594	29,236	25,426	27,432	26,845	25,989
Accumulated deficit	(8,013)	(8,961)	(9,186)	(9,778)	(9,824)	(9,667)
Total stockholders' equity	535	(106)	(692)	(1,022)	(1,279)	(554)
Total liabilities and equity	31,199	29,202	25,686	27,350	26,523	26,366
Common shares outstanding (cover page) millions of shares	356	360	362	365	368	371

Fiscal years (BHC's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(560)	(948)	(225)	(592)	(46)	157
Stock-based compensation	105	128	126	132	150	216
Net cash from operating activities	1,111	1,426	(728)	1,032	1,597	1,400
Purchases of property and equipment	302	269	218	215	337	397
Net cash from investing activities	(261)	409	(303)	(2,145)	(454)	(595)
Proceeds from long-term debt	3,455	2,100	6,836	3,291	661	10,554
Repayments of long-term debt	5,642	3,440	7,846	1,710	1,460	11,191
Net cash from financing activities	(2,294)	(1,513)	(474)	1,475	(868)	(742)
Net change in cash	(1,428)	303	(1,528)	371	239	124

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Vericel	125	77	16*	51.2M	—	Q2 FY26 10-QJun 30, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.